DE69937351D1 - Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten - Google Patents

Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten

Info

Publication number
DE69937351D1
DE69937351D1 DE69937351T DE69937351T DE69937351D1 DE 69937351 D1 DE69937351 D1 DE 69937351D1 DE 69937351 T DE69937351 T DE 69937351T DE 69937351 T DE69937351 T DE 69937351T DE 69937351 D1 DE69937351 D1 DE 69937351D1
Authority
DE
Germany
Prior art keywords
pyrrolocarbazole
entail
contained
particular formulations
forming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69937351T
Other languages
English (en)
Other versions
DE69937351T2 (de
Inventor
David A Dickason
Piyush R Patel
Vincent Corvari
Efraim Shek
Joseph L Herman
Jeffry M Skell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26790393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69937351(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of DE69937351D1 publication Critical patent/DE69937351D1/de
Publication of DE69937351T2 publication Critical patent/DE69937351T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69937351T 1998-08-06 1999-08-06 Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enthalten Expired - Lifetime DE69937351T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US368409 1982-04-14
US9561198P 1998-08-06 1998-08-06
US95611P 1998-08-06
US09/368,409 US6200968B1 (en) 1998-08-06 1999-08-05 Particle-forming compositions containing fused pyrrolocarbazoles
PCT/US1999/017795 WO2000008004A1 (en) 1998-08-06 1999-08-06 Particle-forming compositions containing fused pyrrolocarbazoles

Publications (2)

Publication Number Publication Date
DE69937351D1 true DE69937351D1 (de) 2007-11-29
DE69937351T2 DE69937351T2 (de) 2008-07-17

Family

ID=26790393

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69937351T Expired - Lifetime DE69937351T2 (de) 1998-08-06 1999-08-06 Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enthalten

Country Status (17)

Country Link
US (2) US6200968B1 (de)
EP (1) EP1102758B1 (de)
JP (1) JP2003524597A (de)
KR (1) KR100616388B1 (de)
CN (1) CN1314900A (de)
AT (1) ATE375986T1 (de)
AU (1) AU756865C (de)
CA (1) CA2338546C (de)
CY (1) CY1107855T1 (de)
DE (1) DE69937351T2 (de)
DK (1) DK1102758T3 (de)
ES (1) ES2296401T3 (de)
HK (1) HK1037622A1 (de)
MX (1) MXPA01001352A (de)
NZ (1) NZ509596A (de)
PT (1) PT1102758E (de)
WO (1) WO2000008004A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
MXPA01003761A (es) * 1998-10-13 2003-07-21 Kyowa Hakko Kogyo Kk Agente para tratar oftalmopatia.
KR100911952B1 (ko) 2000-10-11 2009-08-13 세파론, 인코포레이티드 모다피닐 화합물을 포함하는 조성물
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
WO2004009056A1 (en) * 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7255687B2 (en) * 2004-11-19 2007-08-14 Percutaneous Systems, Inc. Systems and methods for luminal access
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2007070444A1 (en) * 2005-12-09 2007-06-21 Abbott Laboratories Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2238973A1 (de) 2009-04-07 2010-10-13 Cephalon France Lyophilisierte Präparate von Proteasominhibitoren
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906108A (en) * 1973-10-12 1975-09-16 Johnson & Johnson Stabilized tretinoin cream emulsion
IE52125B1 (en) * 1980-10-02 1987-06-24 Fox Charles L Jun 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quino-line carboxylic acid and metal salts thereof useful in burn therapy
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
EP0303697B1 (de) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivate des physiologisch aktiven mittels k-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH04124123A (ja) * 1990-08-31 1992-04-24 Kao Corp 口腔用組成物
JP2937446B2 (ja) 1990-09-14 1999-08-23 株式会社資生堂 白髪防止黒化剤
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
IE921315A1 (en) 1991-07-03 1993-01-13 Regeneron Pharma Method and assay system for neurothrophin activity
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
EP0699204B1 (de) 1993-05-28 1998-04-15 Cephalon, Inc. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
AU2999995A (en) * 1994-07-22 1996-02-22 G.D. Searle & Co. Self-emulsifying drug delivery system
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
AU718856B2 (en) * 1996-06-18 2000-04-20 Kyowa Hakko Kogyo Co. Ltd. Liposome preparations of indolocarbazole derivatives
ES2184106T3 (es) * 1996-06-25 2003-04-01 Cephalon Inc Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NZ509596A (en) 2004-07-30
EP1102758A1 (de) 2001-05-30
MXPA01001352A (es) 2002-04-24
CN1314900A (zh) 2001-09-26
KR100616388B1 (ko) 2006-08-29
KR20010079618A (ko) 2001-08-22
ATE375986T1 (de) 2007-11-15
ES2296401T3 (es) 2008-04-16
DE69937351T2 (de) 2008-07-17
WO2000008004A1 (en) 2000-02-17
WO2000008004A8 (en) 2000-06-22
DK1102758T3 (da) 2008-02-04
CA2338546C (en) 2010-02-09
US6200968B1 (en) 2001-03-13
JP2003524597A (ja) 2003-08-19
US6660729B1 (en) 2003-12-09
PT1102758E (pt) 2008-01-23
EP1102758A4 (de) 2002-07-24
AU756865C (en) 2004-02-26
EP1102758B1 (de) 2007-10-17
CA2338546A1 (en) 2000-02-17
AU5467499A (en) 2000-02-28
HK1037622A1 (en) 2002-02-15
CY1107855T1 (el) 2013-06-19
AU756865B2 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
DE69937351D1 (de) Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
IL142254A0 (en) Method for the preparation of stable suspensions of single carbon nanotubes
NO976084L (no) Ny, stabil legemiddeltilberedning for dannelse av drivgassfrie aerosoler
EA200100713A1 (ru) Препаративная форма галантамина с регулируемым выделением
PT1155015E (pt) Processo para a preparação de (e)-(6-¬2-¬4-(4-fluorofenil)-6- isopropil-2-¬metil(metilsulfonil)amino pirimidin-5-il vinil(4r,6s)-2,2-dimetil¬1,3 dioxan-4-il)acetato de terc-butilo
DE69939555D1 (de) Granuliertes Brotverbesserungmittel zur Herstellung von Teigwaren
DE59901682D1 (de) Graphitpartikel enthaltende expandierbare styrolpolymerisate
MY129564A (en) Compositions comprising cefuroxime axetil
ES2196743T3 (es) Sorbitol en polvo y su procedimiento de preparacion.
HK1089772A1 (en) Particle-forming compositions containing fused pyrrolocarbazoles
NO20031754L (no) Fremgangsmåte for fremstilling av mesylater av piperzinderivater
BR9810633A (pt) Composições de detergente lìquido não aquoso contendo partìculas enzimáticas tendo densidade reduzida
NO20004919D0 (no) FremgangsmÕte for fremstilling av 5-hydroksybenzo[b]tiofen-3- karboksylsyrederivater
DE50106179D1 (de) Carotinoidtrockenpulver mit einer Multi-Kern Struktur
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
EA200200294A1 (ru) Сферические агломераты телитромицина, способ их получения и их применение для приготовления лекарственных форм
HRP980585B1 (en) Sulfonamide substituted fused five-membered ring compounds, their use as medicaments as well as pharmaceutical compositions containing them
AU2001258754A1 (en) Aqueous liquid preparation
DK0790994T3 (da) Heterocyclisk substituerede propensyrederivater som NMDA-antagonister
Martyn et al. FORMATION OF AREAS OF PARAMETERS OF FIREPROOF COMPLEXES
Volkov et al. Measuring Mo (110) surface electron density by the method of slow Ar ions scattering; Izmerenie ehlektronnoj plotnosti poverkhnosti Mo (110) metodom rasseyaniya medlennykh ionov Ar
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων
ES2172391B2 (es) Formulacion farmaceutica de una cefalosporina.
NO940011D0 (no) Ultrasmaa, ikke-aggregerte poroese partikler av ensartet stoerrelse for omslutting av gassbobler, samt metoder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition